A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

Three Thoughts on Anixa’s S-3

This afternoon Anixa (ANIX) filed a mixed-shelf offering of up to $100M in securities. Included in this was a sales agreement with B. Riley...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

A Brief Update on Anixa

Yesterday I had the opportunity to sit down with Anixa’s Dr. Amit Kumar, CEO, and Michael Catelani, CFO. Our discussion was rather wide ranging...

Anixa Biosciences to Present at the CYTO 2019 – 34th Congress of the ...

Tailwinds' Take: additional data from the ongoing ResearchDx partnership, which is intended to certify Cchek as a CLIA approved diagnostic, will be presented. Anixa...

B Riley, Day Two Recap

Day two of B Riley was a slightly abbreviated day for yours truly as I had a flight to catch. I did manage to...

Anixa Biosciences Announces Completion of Cchek™ Analytical Verification at CLIA Laboratory

Tallwinds' Take: this important milestone has been achieved within the expected development timeline and Cchek is on track for a Q3 launch. With more...

Bernie Shakes Up Biotech; Anixa Insider Takes Advantage

As the pre-election momentum builds around "MediCare For All", healthcare stocks have become quite jittery. Drug stocks, and in particular the biotech companies, have...

US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology

Tailwinds' Take: this is a very positive step for Anixa as it insures that they have rights to this treatment as a platform for...

Anixa Biosciences Extends and Expands its Collaboration with New Jersey Urology

Tailwinds' Take: I believe investors don't quite get the lack of support for the PSA in the medical community. Cchek, if and when approved,...

Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting

SAN JOSE, Calif., April 3, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to...

Anixa’s CEO to Present at Major Cancer Symposium

On May 15th, Dr. Amit Kumar will be on a panel discussing cancer therapies for solid tumors. This panel is at a conference hosted...

U.S. Department of Veterans Affairs and McGuire Research Institute Join Anixa Biosciences Cchek™ Prostate...

Tailwinds' Take: two keys to this press release. First, this should provide a steady stream of samples, keeping the timeline intact for developing the...

Anixa Biosciences to Present Cchek™ Technology and Data at the Molecular Medicine Tri-Conference

Tailwinds' Take: another oral presentation, at a key conference no less, is going to help Cchek gain recognition right before its launch. Interestingly, data...

Anixa Biosciences to Present Latest Prostate Cancer Data at the 2019 American Association for...

Tailwinds' Take: this is positive for a couple reasons. Oral presentations are not handed out willy-nilly...it shows that the medical community is catching on...

Anixa Partners With ResearchDX…Tailwinds’ Take

This morning, Anixa announced that they have achieved one of their key milestones for 2019, namely that of partnering with an independent clinical laboratory...

Anixa Biosciences Announces Partnership with ResearchDx for Launch of Cchek™ Prostate Cancer Confirmation Test

Tailwinds' Take: Anixa is executing to their plan. Having a diagnostic in the market by Q3 should be eye-opening for institutional investors who have...

Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor...

Tailwinds' Take: working with the leader in MDSC research has enabled the progress of their Cchek diagnostic and will likely lead to more potential...

Oncocyte Jumps, Anixa Should Benefit

Shares in Oncocyte (OCX) are up over 200% today. This move is on the back of positive results from their liquid biopsy diagnostic for...

Anixa Doesn’t Disappoint…

On Thursday January 24th, Anixa Biosciences held an investor update call. In the preview to the call, management had talked about 2019 being a...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.